Braxia Scientific Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Roger McIntyre

Chief Executive Officer (CEO)

CA$170.5k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	4.5yrs
Participación del CEO	5.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Roger McIntyre en comparación con los beneficios de Braxia Scientific?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CA$10m
Sep 30 2023	n/a	n/a	-CA$11m
Jun 30 2023	n/a	n/a	-CA$13m
Mar 31 2023	CA$238k	CA$238k	-CA$13m
Dec 31 2022	n/a	n/a	-CA$12m
Sep 30 2022	n/a	n/a	-CA$13m
Jun 30 2022	n/a	n/a	-CA$12m
Mar 31 2022	CA$300k	CA$300k	-CA$12m
Dec 31 2021	n/a	n/a	-CA$8m
Sep 30 2021	n/a	n/a	-CA$7m
Jun 30 2021	n/a	n/a	-CA$7m
Mar 31 2021	CA$277k	CA$277k	-CA$88m
Mar 31 2020	CA$119k	CA$119k	-CA$3m

Compensación vs. Mercado: La compensación total ($USD122.17K) de Roger está en línea con el promedio de empresas de tamaño similar en el mercado Canadian ($USD169.25K).

Compensación vs. Ingresos: La compensación de Roger ha sido consistente con los resultados de la empresa en el último año.

CEO

Roger McIntyre

4.5yrs

Permanencia

CA$170,500

Compensación

Dr. Roger S. McIntyre, MD., FRCPC., is Chief Executive Officer and Director of Braxia Scientific Corp. since May 11, 2020 and July 22, 2020 respectively and serves as its Chairman of the Board since Octobe...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Roger McIntyre	Chairman & CEO	4.3yrs	CA$170.50k	5.17% CA$ 73.2k
Peter Rizakos	CFO & Director	less than a year	CA$134.04k	sin datos
Jerry Habuda	Independent Director	5.3yrs	sin datos	sin datos
Leann Taylor	Director	2.2yrs	sin datos	sin datos

3.3yrs

Permanencia media

Junta con experiencia: La junta directiva de BRAX se considera experimentada (3.3 años de antigüedad promedio).

Braxia Scientific Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Braxia Scientific Corp., Annual General Meeting, Oct 04, 2024

Less than half of directors are independent

Braxia Scientific Corp. Announces CFO Changes

Braxia Scientific Corp. Appoints Leann Taylor to Board of Directors

Braxia Scientific Corp., Annual General Meeting, Oct 31, 2022

Braxia Scientific Corp. Appoints Jason Wolkove as Chief Information Officer

Recent updates

Braxia Scientific Corp., Annual General Meeting, Oct 04, 2024

Third quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 3Q 2023)

Less than half of directors are independent

Braxia Scientific Corp. Announces CFO Changes

Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.058 loss per share (vs CA$0.069 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.015 loss in 3Q 2022)

Braxia Scientific Corp. announced that it expects to receive CAD 1.5 million in funding

Irwin Naturals Inc. (CNSX:IWIN) signed letter of intent to acquire Braxia Scientific Corp. (CNSX:BRAX) for $30 million.

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 2Q 2022)

Braxia Scientific Corp. Appoints Leann Taylor to Board of Directors

Braxia Scientific Corp. Announces Court Approval of Class Action Settlement in Canada

Braxia Scientific Corp. Announces It Has Successfully Launched KetaMD in Florida

Braxia Scientific Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

Braxia Scientific Corp., Annual General Meeting, Oct 31, 2022

Braxia Scientific Corp. (CNSX:BRAX) acquired 100% stake in KetaMD, Inc.

Full year 2022 earnings released: CA$0.069 loss per share (vs CA$0.56 loss in FY 2021)

Braxia Scientific Corp. Appoints Jason Wolkove as Chief Information Officer

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

Braxia Scientific Corp. Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario

Certification and Hearing to Approve Proposed Settlement of Braxia Scientific Corp. Securities Class Action

High number of new and inexperienced directors

Braxia Scientific Corp. Announces Resignation of David Greenberg as Director

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Braxia Scientific Corp. Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development

Braxia Scientific Corp. announced that it has received CAD 3 million in funding

Braxia Scientific Corp. announced that it expects to receive CAD 3 million in funding

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Braxia Scientific Comments on US Class Action

Braxia Scientific Corp. Launches Psilocybin-Assisted Clinical Therapy Training Program to Develop New Generation of Qualified Physicians, Psychotherapists and Psychologists for Mental Health

Braxia Scientific Corp. Receives Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression

Zhang Investor Law Announces Class Action Lawsuit on Behalf of Shareholders Who Bought Shares of Champignon Brands Inc

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media